Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2001 | 1 |
2004 | 2 |
2005 | 1 |
2007 | 1 |
2010 | 2 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Did you mean
emmett l[au]
(192 results)?
The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Eur J Health Econ. 2005 Mar;6(1):30-7. doi: 10.1007/s10198-004-0254-1.
Eur J Health Econ. 2005.
PMID: 15682286
Review.
What drives quality of life in multiple sclerosis?
Hemmett L, Holmes J, Barnes M, Russell N.
Hemmett L, et al.
QJM. 2004 Oct;97(10):671-6. doi: 10.1093/qjmed/hch105.
QJM. 2004.
PMID: 15367738
Item in Clipboard
Needs assessment of women with urinary incontinence in a district health authority.
MacKay K, Hemmett L.
MacKay K, et al. Among authors: hemmett l.
Br J Gen Pract. 2001 Oct;51(471):801-4.
Br J Gen Pract. 2001.
PMID: 11677702
Free PMC article.
Item in Clipboard
Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.
Moeremans K, et al. Among authors: hemmett l.
Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.
Pharmacoeconomics. 2010.
PMID: 21182349
Item in Clipboard
A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
Holmes J, Dunlop D, Hemmett L, Sharplin P, Bose U.
Holmes J, et al. Among authors: hemmett l.
Pharmacoeconomics. 2004;22(9):581-9. doi: 10.2165/00019053-200422090-00003.
Pharmacoeconomics. 2004.
PMID: 15209527
Item in Clipboard
Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.
Hill A, Hemmett L, Wilson B.
Hill A, et al. Among authors: hemmett l.
HIV Clin Trials. 2007 Sep-Oct;8(5):303-10. doi: 10.1310/hct0805-303.
HIV Clin Trials. 2007.
PMID: 17956831
Item in Clipboard
Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
Hill AM, Gebo K, Hemmett L, Löthgren M, Allegri G, Smets E.
Hill AM, et al. Among authors: hemmett l.
Pharmacoeconomics. 2010;28 Suppl 1:169-81. doi: 10.2165/11587510-000000000-00000.
Pharmacoeconomics. 2010.
PMID: 21182350
Item in Clipboard
Cite
Cite